Compound Detail
CHEMBL1005
REMIFENTANIL 💊 Approved Drug
Enter ChEMBL ID:
Free Research Context
This compound will appear in recent viewed items on the research home for this browser.
Research home
View demo workspace
💊 Approved Drug
Basic Information
| ChEMBL ID | CHEMBL1005 |
| Name | REMIFENTANIL |
| Phase | Approved |
| Structure Type | MOL |
| InChI Key | ZTVQQQVZCWLTDF-UHFFFAOYSA-N |
| Therapeutic | ✓ Yes |
3
Targets
3
Activities
2
Assay Types
6
PK Parameters
14
Publications
7
Known Names
18
Indications
Molecular Properties
376.4
MW (Da)
2.00
ALogP
6
HBA
0
HBD
76.2
PSA (Ų)
0.68
QED
0
Ro5 Violations
7
Rot. Bonds
Drug Information
| Molecule Type | Small molecule |
| First Approval | 1996 |
| Availability | Prescription |
| Chirality | Achiral |
Indications
Breast Diseases Ear Neoplasms Heart Diseases Intelligence Neoplasms Neuralgia, Postherpetic Opioid-Related Disorders Opioid-Related Disorders Pain Shock, Septic Stroke Brain Neoplasms Obesity, Morbid Respiratory Insufficiency Respiratory Insufficiency Premature Birth Sleep Apnea, Obstructive Sleep Apnea Syndromes
ATC Classification
N01AH06
remifentanil
Level 1: NERVOUS SYSTEM
Level 2: ANESTHETICS
Activity Summary
IC50 2 meas. best 9.22
EC50 1 meas. best 8.45
Target Activity Profile
| Target | Type | Best pChEMBL | Mean pChEMBL | Best (nM) | # Data |
|---|---|---|---|---|---|
| Mu-type opioid receptor CHEMBL270 | IC50 | 9.22 | 9.22 | 0.6 | 1 |
| Cavia porcellus CHEMBL369 | EC50 | 8.45 | 8.45 | 3.5 | 1 |
| Voltage-dependent L-type calcium channel subunit alpha-1C CHEMBL1940 | IC50 | 4.41 | 4.41 | 38900.0 | 1 |
Pharmacokinetic Data
| Parameter | Value | Units | Species |
|---|---|---|---|
| CL | 37.0 | mL.min-1.kg-1 | Homo sapiens |
| CL | 37.0 | mL.min-1.kg-1 | Homo sapiens |
| Fu | 0.3 | - | Homo sapiens |
| MRT | 0.18 | hr | Homo sapiens |
| T1/2 | 0.6167 | hr | Homo sapiens |
| T1/2 | 0.8 | hr | Homo sapiens |
Activity Data Samples
Top measurements by pChEMBL value
| Target | Type | Rel. | Value | Units | pChEMBL | Assay | PubMed |
|---|---|---|---|---|---|---|---|
| Mu-type opioid receptor | IC50 | = | 0.6 | nM | 9.22 | Displacement of [3H]DAMGO from rat brain mu opioid receptor incubated for 60 min... | 31391893 |
| Cavia porcellus | EC50 | = | 3.55 | nM | 8.45 | Inhibition of electrically evoked contraction in guinea pig ileum determined in ... | 2066993 |
| Voltage-dependent L-type calcium channel subunit alpha-1C | IC50 | = | 38900.0 | nM | 4.41 | Inhibition of Cav1.2 calcium current measured using whole cell patch clamp in hu... | - |
Literature References
| PubMed | DOI | Target Context | # Activities |
|---|---|---|---|
| 16472241 | 10.2174/1570163043334794 | Hepatotoxicity | 18 |
| 22194678 | 10.1371/journal.pcbi.1002310 | Hepatotoxicity | 14 |
| 18426954 | 10.1124/dmd.108.020479 | ADMET | 4 |
| 2066993 | 10.1021/jm00111a041 | Rattus norvegicus | 2 |
| 19445515 | 10.1021/jm900403j | Homo sapiens | 2 |
| 26948801 | 10.1016/j.drudis.2016.02.015 | Homo sapiens | 2 |
| 31391893 | 10.1039/C9MD00222G | Sigma non-opioid intracellular receptor 1 | 2 |
| - | 10.6019/CHEMBL4651402 | SARS-CoV-2 | 2 |
| 2066993 | 10.1021/jm00111a041 | Cavia porcellus | 1 |
| 2066993 | 10.1021/jm00111a041 | Homo sapiens | 1 |
| 17962026 | 10.1016/j.bmc.2007.10.030 | Mu-opioid receptor | 1 |
| 18426954 | 10.1124/dmd.108.020479 | NON-PROTEIN TARGET | 1 |
| - | 10.1007/s00044-012-9977-1 | Whole blood | 1 |
| 31391893 | 10.1039/C9MD00222G | Mu-type opioid receptor | 1 |
Data from ChEMBL 36 via Core Engine